<p>Twelve Points Wealth Management LLC 在最近向證券交易委員會（SEC）提交的文件中表示，在第四季度將其在化工公司 Chemours（紐約證券交易所代碼：CC - 免費報告）的持股增加了 42.8%。該機構投資者在此期間購買了額外的 23,490 股後，持有 78,325 股該公司的股票。截至其最近向證券交易委員會（SEC）提交的文件，Twelve Points Wealth Management LLC 持有 Chemours 約 0.05% 的股份，價值 1,324,000 美元。</p>
<ul>
<li>人工智能需求為這三家核能領導者帶來機會</li>
</ul>
<p>其他對沖基金最近也增加或減少了對該公司的持股。KBC Group NV 在第三季度將其在 Chemours 的持股增加了 19.5%。KBC Group NV 目前持有 4,468 股該公司的股票，價值 91,000 美元，此前在上個季度購買了 728 股。Blue Trust Inc.在第三季度將其在 Chemours 的持股增加了 166.9%。Blue Trust Inc.目前持有 1,169 股該公司的股票，價值 26,000 美元，此前在上個季度購買了 731 股。GAMMA Investing LLC 在第四季度將其在 Chemours 的持股增加了 99.7%。GAMMA Investing LLC 目前持有 1,532 股該公司的股票，價值 26,000 美元，此前在上個季度購買了 765 股。阿拉斯加州財政部在第三季度將其在 Chemours 的持股增加了 7.3%。阿拉斯加州財政部目前持有 17,205 股該公司的股票，價值 349,000 美元，此前在此期間購買了 1,175 股。最後，Signaturefd LLC 在第三季度將其在 Chemours 的持股增加了 163.7%。Signaturefd LLC 目前持有 1,959 股該公司的股票，價值 40,000 美元，此前在上個季度購買了 1,216 股。76.26% 的股票由機構投資者和對沖基金持有。</p>
<h2>內部人員買賣</h2>
<p>在其他消息中，SVP Alvenia Scarborough 於 11 月 7 日星期四出售了 7,500 股該公司的股票。股票以平均價格 20.64 美元出售，總交易額為 154,800.00 美元。出售完成後，這位高級副總裁現在持有 16,645 股該公司的股票，價值 343,552.80 美元。這代表了他們持股的 31.06% 的減少。該交易在向證券交易委員會的文件中披露，相關信息可通過此鏈接獲取。當前 0.47% 的股票由內部人員持有。</p>
<h2>分析師評級變動</h2>
<ul>
<li>嘉年華：2025 年投資這隻股票的四個理由</li>
</ul>
<p>CC 已成為多份研究報告的主題。BMO 資本市場在 10 月 7 日的報告中將 Chemours 的目標股價從 30.00 美元提高至 32.00 美元，並給予該股票 “跑贏大盤” 的評級。巴克萊在 11 月 5 日的研究報告中將 Chemours 的目標股價從 21.00 美元提高至 23.00 美元，並給予該股票 “持平” 的評級。高盛在 1 月 7 日的研究報告中將 Chemours 的目標股價從 24.00 美元下調至 21.00 美元，並對該公司設定了 “中性” 的評級。瑞穗在 1 月 7 日的研究報告中將 Chemours 的目標股價從 22.00 美元下調至 21.00 美元，並對該股票設定了 “中性” 的評級。最後，Truist Financial 在週二開始對 Chemours 進行覆蓋。他們對該公司設定了 “買入” 評級和 27.00 美元的目標股價。五位股票研究分析師對該股票給予了持有評級，四位分析師給予了買入評級。根據 MarketBeat 的數據，Chemours 目前的平均評級為 “持有”，平均目標股價為 24.11 美元。</p>
<p><strong>獲取我們對 CC 的最新分析</strong></p>
<h2>Chemours 股價下跌 1.8%</h2>
<ul>
<li>打破常規：三隻非科技股準備在 2025 年大幅上漲</li>
</ul>
<p>CC 股票在週三開盤價為 18.76 美元。Chemours 公司的 1 年最低價為 15.10 美元，1 年最高價為 31.76 美元。該公司的市值為 28 億美元，市盈率為 37.51，貝塔值為 1.83。該公司的債務與股本比率為 6.05，流動比率為 1.73，速動比率為 0.92。該股票的 50 日簡單移動平均線為 19.18 美元，200 日簡單移動平均線為 19.55 美元。</p>
<p>Chemours（紐約證券交易所代碼：CC - 獲取免費報告）最近於 11 月 4 日星期一發布了季度財報。這家特種化學公司報告本季度每股收益（EPS）為 0.40 美元，超出市場共識預期的 0.32 美元，超出幅度為 0.08 美元。該公司本季度的收入為 15 億美元，而市場共識預期為 14.4 億美元。Chemours 的淨利潤率為 1.34%，股本回報率為 29.48%。與去年同期相比，該公司的收入增長了 0.9%。去年同期，該公司每股收益為 0.64 美元。股票研究分析師預計 Chemours 公司在當前財年將發佈 1.19 美元的每股收益。</p>
<h2>Chemours 公司簡介</h2>
<p>（免費報告）</p>
<p>Chemours 公司在北美、亞太地區、歐洲、中東、非洲和拉丁美洲提供性能化學品。它通過三個部門運營：鈦技術、熱能與專業解決方案，以及先進性能材料。鈦技術部門提供 TiO2 顏料，品牌為 Ti-Pure，用於在各種應用中提供白度、亮度、不透明度、耐用性、效率和保護，例如建築和工業塗料、柔性和剛性塑料包裝、聚氯乙烯、用於傢俱和建築材料的層壓紙、塗層紙和用於包裝的塗層紙板。</p>
<h2>特色文章</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Chemours</li>
<li>ETF 會支付股息嗎？你需要知道的事項</li>
<li>蘋果股價反彈：在財報發佈前值得購買嗎？</li>
<li>3 只股票引領 meme 股票復興</li>
<li>美國航空：行業逆風還是內部缺陷？</li>
<li>什麼是股息競爭者？投資股息競爭者</li>
<li>3 只運輸股票引領市場動能</li>
</ul>
<p><strong>想看看其他對 CC 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取最新的 13F 文件和 The Chemours Company (NYSE:CC - 免費報告) 的內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUND?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUND"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Chemours 嗎？</h2>
<p>在考慮 Chemours 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前立即購買的股票……而 Chemours 並不在名單上。</p>
<p>雖然 Chemours 目前在分析師中被評為 “持有”，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Twelve Points Wealth Management LLC 在第四季度將其在化工公司（NYSE:CC）的股份增加了 42.8%，持有 78,325 股，價值 132 萬美元。其他機構投資者也調整了他們的持股。內部人士 Alvenia Scarborough 出售了 7,500 股，減少了 31.06% 的持股比例。分析師的評級不一，目標價範圍從 21 美元到 32 美元不等。Chemours 的股票開盤價為 18.76 美元，市值為 28 億美元，市盈率為 37.51</p>

<p>Twelve Points Wealth Management LLC boosted its holdings in shares of The Chemours Company (NYSE:CC - Free Report) by 42.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,325 shares of the specialty chemicals company's stock after buying an additional 23,490 shares during the period. Twelve Points Wealth Management LLC owned approximately 0.05% of Chemours worth $1,324,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Twelve Points Wealth Management LLC 在最近向證券交易委員會（SEC）提交的文件中表示，在第四季度將其在化工公司 Chemours（紐約證券交易所代碼：CC - 免費報告）的持股增加了 42.8%。該機構投資者在此期間購買了額外的 23,490 股後，持有 78,325 股該公司的股票。截至其最近向證券交易委員會（SEC）提交的文件，Twelve Points Wealth Management LLC 持有 Chemours 約 0.05% 的股份，價值 1,324,000 美元。</p>
</div><ul>
<li>AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders</li>
</ul>
<div class="lb-trans"><ul>
<li>人工智能需求為這三家核能領導者帶來機會</li>
</ul>
</div><p>Other hedge funds also recently added to or reduced their stakes in the company. KBC Group NV grew its holdings in shares of Chemours by 19.5% during the third quarter. KBC Group NV now owns 4,468 shares of the specialty chemicals company's stock valued at $91,000 after buying an additional 728 shares during the last quarter. Blue Trust Inc. grew its stake in Chemours by 166.9% during the 3rd quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock valued at $26,000 after purchasing an additional 731 shares during the last quarter. GAMMA Investing LLC grew its stake in Chemours by 99.7% during the 4th quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock valued at $26,000 after purchasing an additional 765 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in shares of Chemours by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 17,205 shares of the specialty chemicals company's stock valued at $349,000 after purchasing an additional 1,175 shares during the period. Finally, Signaturefd LLC raised its stake in shares of Chemours by 163.7% in the third quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company's stock worth $40,000 after purchasing an additional 1,216 shares during the last quarter. 76.26% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他對沖基金最近也增加或減少了對該公司的持股。KBC Group NV 在第三季度將其在 Chemours 的持股增加了 19.5%。KBC Group NV 目前持有 4,468 股該公司的股票，價值 91,000 美元，此前在上個季度購買了 728 股。Blue Trust Inc.在第三季度將其在 Chemours 的持股增加了 166.9%。Blue Trust Inc.目前持有 1,169 股該公司的股票，價值 26,000 美元，此前在上個季度購買了 731 股。GAMMA Investing LLC 在第四季度將其在 Chemours 的持股增加了 99.7%。GAMMA Investing LLC 目前持有 1,532 股該公司的股票，價值 26,000 美元，此前在上個季度購買了 765 股。阿拉斯加州財政部在第三季度將其在 Chemours 的持股增加了 7.3%。阿拉斯加州財政部目前持有 17,205 股該公司的股票，價值 349,000 美元，此前在此期間購買了 1,175 股。最後，Signaturefd LLC 在第三季度將其在 Chemours 的持股增加了 163.7%。Signaturefd LLC 目前持有 1,959 股該公司的股票，價值 40,000 美元，此前在上個季度購買了 1,216 股。76.26% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人員買賣</h2>
</div><p>In other news, SVP Alvenia Scarborough sold 7,500 shares of the company's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the completion of the sale, the senior vice president now owns 16,645 shares of the company's stock, valued at $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. 0.47% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，SVP Alvenia Scarborough 於 11 月 7 日星期四出售了 7,500 股該公司的股票。股票以平均價格 20.64 美元出售，總交易額為 154,800.00 美元。出售完成後，這位高級副總裁現在持有 16,645 股該公司的股票，價值 343,552.80 美元。這代表了他們持股的 31.06% 的減少。該交易在向證券交易委員會的文件中披露，相關信息可通過此鏈接獲取。當前 0.47% 的股票由內部人員持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>Carnival: 4 Reasons to Set Sail in This Stock in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>嘉年華：2025 年投資這隻股票的四個理由</li>
</ul>
</div><p>CC has been the topic of several research reports. BMO Capital Markets increased their price target on shares of Chemours from $30.00 to $32.00 and gave the stock an &#34;outperform&#34; rating in a report on Monday, October 7th. Barclays increased their price objective on shares of Chemours from $21.00 to $23.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Tuesday, November 5th. The Goldman Sachs Group decreased their target price on shares of Chemours from $24.00 to $21.00 and set a &#34;neutral&#34; rating for the company in a research report on Tuesday, January 7th. Mizuho cut their price target on Chemours from $22.00 to $21.00 and set a &#34;neutral&#34; rating on the stock in a research report on Tuesday, January 7th. Finally, Truist Financial began coverage on Chemours in a research note on Tuesday. They set a &#34;buy&#34; rating and a $27.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Chemours presently has an average rating of &#34;Hold&#34; and an average target price of $24.11.</p>
<div class="lb-trans"><p>CC 已成為多份研究報告的主題。BMO 資本市場在 10 月 7 日的報告中將 Chemours 的目標股價從 30.00 美元提高至 32.00 美元，並給予該股票 “跑贏大盤” 的評級。巴克萊在 11 月 5 日的研究報告中將 Chemours 的目標股價從 21.00 美元提高至 23.00 美元，並給予該股票 “持平” 的評級。高盛在 1 月 7 日的研究報告中將 Chemours 的目標股價從 24.00 美元下調至 21.00 美元，並對該公司設定了 “中性” 的評級。瑞穗在 1 月 7 日的研究報告中將 Chemours 的目標股價從 22.00 美元下調至 21.00 美元，並對該股票設定了 “中性” 的評級。最後，Truist Financial 在週二開始對 Chemours 進行覆蓋。他們對該公司設定了 “買入” 評級和 27.00 美元的目標股價。五位股票研究分析師對該股票給予了持有評級，四位分析師給予了買入評級。根據 MarketBeat 的數據，Chemours 目前的平均評級為 “持有”，平均目標股價為 24.11 美元。</p>
</div><p><strong>Get Our Latest Analysis on CC</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 CC 的最新分析</strong></p>
</div><h2>Chemours Trading Down 1.8 %</h2>
<div class="lb-trans"><h2>Chemours 股價下跌 1.8%</h2>
</div><ul>
<li>Breaking the Mold: 3 Non-Tech Stocks Ready to Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>打破常規：三隻非科技股準備在 2025 年大幅上漲</li>
</ul>
</div><p>Shares of CC stock opened at $18.76 on Wednesday. The Chemours Company has a 1-year low of $15.10 and a 1-year high of $31.76. The company has a market cap of $2.80 billion, a price-to-earnings ratio of 37.51 and a beta of 1.83. The company has a debt-to-equity ratio of 6.05, a current ratio of 1.73 and a quick ratio of 0.92. The stock has a 50 day simple moving average of $19.18 and a 200-day simple moving average of $19.55.</p>
<div class="lb-trans"><p>CC 股票在週三開盤價為 18.76 美元。Chemours 公司的 1 年最低價為 15.10 美元，1 年最高價為 31.76 美元。該公司的市值為 28 億美元，市盈率為 37.51，貝塔值為 1.83。該公司的債務與股本比率為 6.05，流動比率為 1.73，速動比率為 0.92。該股票的 50 日簡單移動平均線為 19.18 美元，200 日簡單移動平均線為 19.55 美元。</p>
</div><p>Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.08. The business had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The company's revenue was up .9% compared to the same quarter last year. During the same period last year, the firm posted $0.64 earnings per share. On average, equities research analysts expect that The Chemours Company will post 1.19 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Chemours（紐約證券交易所代碼：CC - 獲取免費報告）最近於 11 月 4 日星期一發布了季度財報。這家特種化學公司報告本季度每股收益（EPS）為 0.40 美元，超出市場共識預期的 0.32 美元，超出幅度為 0.08 美元。該公司本季度的收入為 15 億美元，而市場共識預期為 14.4 億美元。Chemours 的淨利潤率為 1.34%，股本回報率為 29.48%。與去年同期相比，該公司的收入增長了 0.9%。去年同期，該公司每股收益為 0.64 美元。股票研究分析師預計 Chemours 公司在當前財年將發佈 1.19 美元的每股收益。</p>
</div><h2>Chemours Company Profile</h2>
<div class="lb-trans"><h2>Chemours 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal &amp; Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.</p>
<div class="lb-trans"><p>Chemours 公司在北美、亞太地區、歐洲、中東、非洲和拉丁美洲提供性能化學品。它通過三個部門運營：鈦技術、熱能與專業解決方案，以及先進性能材料。鈦技術部門提供 TiO2 顏料，品牌為 Ti-Pure，用於在各種應用中提供白度、亮度、不透明度、耐用性、效率和保護，例如建築和工業塗料、柔性和剛性塑料包裝、聚氯乙烯、用於傢俱和建築材料的層壓紙、塗層紙和用於包裝的塗層紙板。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Chemours</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>Apple Swings to Outperformer: Is It a Buy Ahead of Earnings?</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>American Airlines: Industry Headwinds or Internal Flaws?</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>3 Trucking Stocks Leading the Way in Market Momentum</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Chemours</li>
<li>ETF 會支付股息嗎？你需要知道的事項</li>
<li>蘋果股價反彈：在財報發佈前值得購買嗎？</li>
<li>3 只股票引領 meme 股票復興</li>
<li>美國航空：行業逆風還是內部缺陷？</li>
<li>什麼是股息競爭者？投資股息競爭者</li>
<li>3 只運輸股票引領市場動能</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CC?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 CC 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取最新的 13F 文件和 The Chemours Company (NYSE:CC - 免費報告) 的內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUND" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=CC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Chemours Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Chemours 嗎？</h2>
</div><p>Before you consider Chemours, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Chemours 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前立即購買的股票……而 Chemours 並不在名單上。</p>
</div><p>While Chemours currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Chemours 目前在分析師中被評為 “持有”，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

十二點財富管理有限責任公司購買了 Chemours 公司（NYSE:CC）的股票